- Proprietary data and samples from TRACERx and Achilles’ Material Acquisition Platform (MAP) will be transferred to AstraZeneca under the Transaction -

Follow this link:
Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca

Global News Feed Comments Off on Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca | December 27th, 2024

Company announcement – No. 52 / 2024

View post:
Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.

Global News Feed Comments Off on Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc. | December 27th, 2024

TEL AVIV, Israel, Dec. 26, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), announced that AutoMax Motors Ltd., (“AutoMax”), a leading automotive importer and distributor in Israel with which the Company has entered into an agreement and plan of merger, received its first shipment of vehicles manufactured by Anhui Jianghuai Automobile Group Co., Ltd. (“JAC Motors”), a globally recognized Chinese automotive company. This marks a significant milestone in AutoMax’s direct import and distribution operations, launched under agreements signed earlier this year with JAC Motors.

See the rest here:
SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

Global News Feed Comments Off on SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation | December 27th, 2024

Company recently signed a non-binding term sheet with Dr Glitter Pty Ltd for mutual development in ActivCrystal™ Format

Read more:
Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute

Global News Feed Comments Off on Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute | December 27th, 2024

YARDLEY, Pa., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Optinose, Inc. (NASDAQ: OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it will effect a 1-for-15 reverse stock split at 5:00 p.m. Eastern Standard Time, on December 30, 2024. Beginning with the opening of trading on December 31, 2024, Optinose’s common stock will trade on the Nasdaq Global Select Market (“Nasdaq”) on a split-adjusted basis under a new CUSIP number 68404V209 and Optinose’s existing trading symbol “OPTN.”

Read more from the original source:
Optinose Announces 1-for-15 Reverse Stock Split

Global News Feed Comments Off on Optinose Announces 1-for-15 Reverse Stock Split | December 27th, 2024

– ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing observed –

Read more from the original source:
Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in...

Global News Feed Comments Off on Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in… | December 27th, 2024

WARREN, N.J., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), will host panel discussions at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California.

View original post here:
Tevogen Bio to Host Panel Discussions “AI In Biopharma: Next Frontier of Medical Innovation” and “Pioneering the Economics of Health: Balancing...

Global News Feed Comments Off on Tevogen Bio to Host Panel Discussions “AI In Biopharma: Next Frontier of Medical Innovation” and “Pioneering the Economics of Health: Balancing… | December 27th, 2024

SAN DIEGO, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that its Board of Directors has initiated a process to explore a broad range of strategic alternatives.

See the original post:
Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives

Global News Feed Comments Off on Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives | December 27th, 2024

Wuxi, China, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Park Ha Biological Technology Co., Ltd. (the "Company"), a company focused on developing private skincare labels, direct skincare product sales, and franchise alliance promotions, today announced the pricing of its initial public offering (the "Offering") of 1,200,000 ordinary shares at a public offering price of $4.00 per ordinary share. The ordinary shares have been approved for listing on the Nasdaq Capital Market and are expected to commence trading on December 27, 2024 under the ticker symbol "PHH."

Visit link:
Park Ha Biological Technology Co., Ltd. Announces Pricing of $4.8 Million Initial Public Offering

Global News Feed Comments Off on Park Ha Biological Technology Co., Ltd. Announces Pricing of $4.8 Million Initial Public Offering | December 27th, 2024

VYVDURA® now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDP

Link:
argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating...

Global News Feed Comments Off on argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating… | December 27th, 2024

Stem cell transplants are used to put blood stem cells back into the body after the bone marrow has been destroyed by disease, chemotherapy (chemo), or radiation. Depending on where the stem cells come from, the transplant procedure may go by different names:

All of these can also be calledhematopoietic stem cell transplants.

In a typical stem cell transplant for cancer, a person first gets very high doses of chemo, sometimes along with radiation therapy, to try to kill all the cancer cells. This treatment also kills the stem cells in the bone marrow. This is called myeloablation or myeloablative therapy.

Soon after treatment, blood stem cells are given (transplanted) to replace those that were destroyed. The replacement stem cells are given into a vein, much like ablood transfusion. The goal is that over time, the transplanted cells will settle in the bone marrow, where they will begin to grow and make healthy new blood cells. This process is called engraftment.

There are 2 main types of transplants. They are named based on who donates the stem cells.

In this type of transplant, the first step is to remove or harvest your own stem cells. Your stem cells are removed from either your bone marrow or your blood, and then frozen. (You can learn more about this process at Whats It Like to Donate Stem Cells?) After you get high doses of chemo and/or radiation as your myeloablative therapy, the stem cells are thawed and given back to you.

This kind of transplant is mainly used to treat certain leukemias, lymphomas, and multiple myeloma. Its sometimes used for other cancers, like testicular cancer and neuroblastoma, and certain cancers in children. Doctors can use autologous transplants for other diseases, too, like systemic sclerosis, multiple sclerosis (MS), Crohn's disease, and systemic lupus erythematosus (lupus).

An advantage of an autologous stem cell transplantis that youre getting your own cells back. When you get your own stem cells back, you dont have to worry about them (called the engrafted cells or the graft) being rejected by your body. You also dont have to worry about immune cells from the transplant attacking healthy cells in your body (known as graft-versus-host disease), which is a concern with allogeneic transplants.

An autologous transplant graft might still fail, which means the transplanted stem cells dont go into the bone marrow and make blood cells like they should.

Also, autologous transplants cant produce the graft-versus-cancer effect, in which the donor immune cells from the transplant help kill any cancer cells that remain.

Another possible disadvantage of an autologous transplant is that cancer cells might be collected along with the stem cells and then later be put back into your body.

To help prevent any remaining cancer cells from being transplanted along with stem cells, some centers treat the stem cells before theyre given back to the patient. This may be called purging. While this might work for some patients, there haven't been enough studies yet to know if this is really a benefit. A possible downside of purging is that some normal stem cells can be lost during this process. This may cause your body to take longer to start making normal blood cells, and you might have very low and unsafe levels of white blood cells or platelets for a longer time. This could increase the risk of infections or bleeding problems.

Another treatment to help kill cancer cells that might be in the returned stem cells involves giving anti-cancer drugs after the transplant. The stem cells are not treated. After transplant, the patient gets anti-cancer drugs to get rid of any cancer cells that may be in the body. This is called in vivo purging. For instance, lenalidomide (Revlimid) may be used in this way for multiple myeloma. The need to remove cancer cells from transplanted stem cells or transplant patients and the best way to do it continues to be researched.

Doing 2 autologous transplants in a row is known as a tandem transplant or a double autologous transplant. In this type of transplant, the patient gets 2 courses of high-dose chemo as myeloablative therapy, each followed by a transplant of their own stem cells. All of the stem cells needed are collected before the first high-dose chemo treatment, and half of them are used for each transplant. Usually, the 2 courses of chemo are given within 6 months. The second one is given after the patient recovers from the first one.

Tandem transplants have become the standard of care for certain cancers. High-risk types of the childhood cancer neuroblastoma and adult multiple myeloma are cancers where tandem transplants seem to show good results. But doctors dont always agree that these are really better than a single transplant for certain cancers. Because this treatment involves 2 transplants, the risk of serious outcomes is higher than for a single transplant.

Sometimes an autologous transplant followed by an allogeneic transplant might also be called a tandem transplant. (See Mini-transplants below.)

Allogeneic stem cell transplants use donor stem cells. In the most common type of allogeneic transplant, the stem cells come from a donor whose tissue type closely matches yours. (This is discussed in Matching patients and donors.) The best donor is a close family member, usually a brother or sister. If you dont have a good match in your family, a donor might be found in the general public through a national registry. This is sometimes called a MUD (matched unrelated donor) transplant. Transplants with a MUD are usually riskier than those with a relative who is a good match.

An allogeneic transplant works about the same way as an autologous transplant. Stem cells are collected from the donor and stored or frozen. After you get high doses of chemo and/or radiation as your myeloablative therapy, the donor's stem cells are thawed and given to you.

Allogeneic transplants are most often used to treat certain types of leukemia, lymphomas, multiple myeloma, myelodysplastic syndromes, and other bone marrow disorders such as aplastic anemia.

Blood taken from the placenta and umbilical cord after a baby is born can also be used for an allogeneic transplant. This small volume of cord blood has a high number of stem cells in it.

Cord blood transplants can have some advantages. For example, there are already a large number of donated units in cord blood banks, so finding a donor match might be easier. These units have already been donated, so they dont need to be collected once a match is found. A cord blood transplant is also less likely to be rejected by your body than is a transplant from an adult donor.

But cord blood transplants can have some downsides as well. There arent as many stem cells in a cord blood unit as there are in a typical transplant from an adult donor. Because of this, cord blood transplants are used more often for children, who have smaller body sizes. These transplants can be used for adults as well, although sometimes a person might need to get more than one cord blood unit to help ensure there are enough stem cells for the transplant.

Cord blood transplants can also take longer to begin making new blood cells, during which time a person is vulnerable to infections and other problems caused by having low blood cell counts. For a newer cord blood product, known as omidubicel (Omisirge), the cord blood cells are treated in a lab with a special chemical, which helps them get to the bone marrow and start making new blood cells quicker once theyre in the body.

A major benefit of allogeneic transplants is that the donor stem cells make their own immune cells, which could help kill any cancer cells that remain after high-dose treatment. This is called the graft-versus-cancer or graft-versus-tumor effect.

Other advantages are that the donor can often be asked to donate more stem cells or even white blood cells if needed (although this isn't true for a cord blood transplant), and stem cells from healthy donors are free of cancer cells.

As with any type of transplant, there is a risk that the transplant, or graft, might not take that is, the transplanted donor stem cells could die or be destroyed by the patients body before settling in the bone marrow.

Another risk is that the immune cells from the donor could attack healthy cells in the patients body. This is called graft-versus-host disease, and it can range from mild to life-threatening.

There is also a very small risk of certain infections from the donor cells, even though donors are tested before they donate.

Another risk is that some types of infections you had previously and which your immune system has had under control may resurface after an allogeneic transplant. This can happen when your immune system is weakened (suppressed) by medicines called immunosuppressive drugs. Such infections can cause serious problems and can even be life-threatening.

For some people, age or certain health conditions make it more risky to do myeloablative therapy that wipes out all of their bone marrow before a transplant. For those people, doctors can use a type of allogeneic transplant thats sometimes called a mini-transplant. Your doctor might refer to it as a non-myeloablative transplant or mention reduced-intensity conditioning (RIC). Patients getting a mini transplant typically get lower doses of chemo and/or radiation than if they were getting a standard myeloablative transplant. The goal in the mini-transplant is to kill some of the cancer cells (which will also kill some of the bone marrow), and suppress the immune system just enough to allow donor stem cells to settle in the bone marrow.

Unlike the standard allogeneic transplant, cells from both the donor and the patient exist together in the patients body for some time after a mini-transplant. But slowly, over the course of months, the donor cells take over the bone marrow and replace the patients own bone marrow cells. These new cells can then develop an immune response to the cancer and help kill off the patients cancer cells the graft-versus-cancer effect.

One advantage of a mini-transplant is that it uses lower doses of chemo and/or radiation. And because the stem cells arent all killed, blood cell counts dont drop as low while waiting for the new stem cells to start making normal blood cells. This makes it especially useful for older patients and those with other health problems. Rarely, it may be used in patients who have already had a transplant.

Mini-transplants treat some diseases better than others. They may not work well for patients with a lot of cancer in their body or people with fast-growing cancers. Also, although there might be fewer side effects from chemo and radiation than those from a standard allogeneic transplant, the risk of graft-versus-host disease is the same. Some studies have shown that for some cancers and some other blood conditions, both adults and children can have the same kinds of results with a mini-transplant as compared to a standard transplant.

This is a special kind of allogeneic transplant that can only be used when the patient has an identical sibling (twin or triplet) someone who has the exact same tissue type. An advantage of syngeneic stem cell transplant is that graft-versus-host disease will not be a problem. Also, there are no cancer cells in the transplanted stem cells, as there might be in an autologous transplant.

A disadvantage is that because the new immune system is so much like the recipients immune system, theres no graft-versus-cancer effect. Every effort must be made to destroy all the cancer cells before the transplant is done to help keep the cancer from coming back.

Improvements have been made in the use of family members as donors. This kind of transplant is called ahalf-match (haploidentical) transplant for people who dont have fully matching or identical family member. This can be another option to consider, along with cord blood transplant and matched unrelated donor (MUD) transplant.

If possible, it is very important that the donor and recipient are a close tissue match to avoid graft rejection. Graft rejection happens when the recipients immune system recognizes the donor cells as foreign and tries to destroy them as it would a bacteria or virus. Graft rejection can lead to graft failure, but its rare when the donor and recipient are well matched.

A more common problem is that when the donor stem cells make their own immune cells, the new cells may see the patients cells as foreign and attack their new home. This is called graft-versus-host disease. (See Stem Cell Transplant Side Effects for more on this). The new, grafted stem cells attack the body of the person who got the transplant. This is another reason its so important to find the closest match possible.

Many factors play a role in how the immune system knows the difference between self and non-self, but the most important for transplants is the human leukocyte antigen (HLA) system. Human leukocyte antigens are proteins found on the surface of most cells. They make up a persons tissue type, which is different from a persons blood type.

Each person has a number of pairs of HLA antigens. We inherit them from both of our parents and, in turn, pass them on to our children. Doctors try to match these antigens when finding a donor for a person getting a stem cell transplant.

How well the donors and recipients HLA tissue types match plays a large part in whether the transplant will work. A match is best when all 6 of the known major HLA antigens are the same a 6 out of 6 match. People with these matches have a lower chance of graft-versus-host disease, graft rejection, having a weak immune system, and getting serious infections. For bone marrow and peripheral blood stem cell transplants, sometimes a donor with a single mismatched antigen is used a 5 out of 6 match. For cord blood transplants a perfect HLA match doesnt seem to be as important, and even a sample with a couple of mismatched antigens may be OK.

Doctors keep learning more about better ways to match donors. Today, fewer tests may be needed for siblings, since their cells vary less than an unrelated donor. But to reduce the risks of mismatched types between unrelated donors, more than the basic 6 HLA antigens may be tested. For example, sometimes doctors to try and get a 10 out of 10 match. Certain transplant centers now require high-resolution matching, which looks more deeply into tissue types and allow more specific HLA matching.

There are thousands of different combinations of possible HLA tissue types. This can make it hard to find an exact match. HLA antigens are inherited from both parents. If possible, the search for a donor usually starts with the patients brothers and sisters (siblings), who have the same parents as the patient. The chance that any one sibling would be a perfect match (that is, that you both received the same set of HLA antigens from each of your parents) is 1 out of 4.

If a sibling is not a good match, the search could then move on to relatives who are less likely to be a good match parents, half siblings, and extended family, such as aunts, uncles, or cousins. (Spouses are no more likely to be good matches than other people who are not related.) If no relatives are found to be a close match, the transplant team will widen the search to the general public.

As unlikely as it seems, its possible to find a good match with a stranger. To help with this process, the team will use transplant registries, like those listed here. Registries serve as matchmakers between patients and volunteer donors. They can search for and access millions of possible donors and hundreds of thousands of cord blood units.

Be the Match (formerly the National Marrow Donor Program)Toll-free number: 1-800-MARROW-2 (1-800-627-7692)Website: http://www.bethematch.org

Blood & Marrow Transplant Information NetworkToll-free number: 1-888-597-7674Website: http://www.bmtinfonet.org

Depending on a persons tissue typing, several other international registries also are available. Sometimes the best matches are found in people with a similar racial or ethnic background. When compared to other ethnic groups, white people have a better chance of finding a perfect match for stem cell transplant among unrelated donors. This is because ethnic groups have differing HLA types, and in the past there was less diversity in donor registries, or fewer non-White donors. However, the chances of finding an unrelated donor match improve each year, as more volunteers become aware of registries and sign up for them.

Finding an unrelated donor can take months, though cord blood may be a little faster. A single match can require going through millions of records. Also, now that transplant centers are more often using high-resolution tests, matching is becoming more complex. Perfect 10 out of 10 matches at that level are much harder to find. But transplant teams are also getting better at figuring out what kinds of mismatches can be tolerated in which particular situations that is, which mismatched antigens are less likely to affect transplant success and survival.

Keep in mind that there are stages to this process there may be several matches that look promising but dont work out as hoped. The team and registry will keep looking for the best possible match for you. If your team finds an adult donor through a transplant registry, the registry will contact the donor to set up the final testing and donation. If your team finds matching cord blood, the registry will have the cord blood sent to your transplant center.

Originally posted here:
Types of Stem Cell and Bone Marrow Transplants

Bone Marrow Stem Cells Comments Off on Types of Stem Cell and Bone Marrow Transplants | December 27th, 2024

A pilot raced through the airport to surprise an old friend: the woman who saved his life  CNN

Read more from the original source:
A pilot raced through the airport to surprise an old friend: the woman who saved his life - CNN

Bone Marrow Stem Cells Comments Off on A pilot raced through the airport to surprise an old friend: the woman who saved his life – CNN | December 27th, 2024

Heart disease, whether inherited or acquired, is the leading cause of mortality in both men and women worldwide, accounting for 17.3 million deaths per year.1 The urgent need to improve existing therapies has driven researchers to seek a better understanding of the diverse but inter-related mechanistic origins of heart development and failure, with the ultimate goals of identifying novel pharmacological treatments and/or cell-based engineering approaches to replace damaged heart tissue. Animal models are widely used as surrogates for studying human disease, both in order to recapitulate the complex clinical course of human heart failure and to generate in vitro tools for studying specific aspects of tissue dysfunction.2 Although useful insights have been gained, experimental findings from animal models have not always extrapolated to human disease presentation due to considerable species variation3. Here we describe prominent routes taken towards the goal of cardiac regeneration by focusing on key contributing papers published by Circulation Research in the 60 years since its establishment.

Multipotent adult stem cells have been the focus of most preclinical and clinical studies carried out to date in the field of cardiac regeneration. They represent an attractive source of stem cells since they are relatively abundant, accessible and autologous, and their mechanisms of action for any observed improvement in cardiac function can be potentially delineated. In 1998, Anversa et al. published a field-changing paper challenging the notion that the myocardium is a non-regenerating tissue, by describing the presence of multipotent cardiac stem cells (CSCs) in the adult myocardium that are positive for the hematopoietic progenitor marker c-kit.4 Methods for isolating functionally competent CSCs and mechanisms proving that their activation can reverse cardiac dysfunction were later published by the same group.5, 6 It was this pioneering work and the ability to adequately expand CSCs ex vivo that formed the basis for the first randomized clinical trial of CSC implant in ischemic heart disease patients (SCIPIO trial).7 Phase I of the trial demonstrated a sound safety profile and potential for efficacy in improving ventricular function. In 2004, Messina et al. were able to isolate and expand c-kit+ CSCs from adult murine hearts as self-adherent clusters of progenitor cells, termed cardiospheres.8 This isolation technique later became feasible for human hearts and was used to test the therapeutic efficacy of cardiosphere-derived cells (CDCs) in the CADUCEUS trial.9 The Phase I trial demonstrated a good safety profile and potential for reducing in scar size and regional function compared to controls. More recently, Dey et al. performed detailed characterization of multiple stem cell populations and concluded that c-kit+ CSCs represent the most primitive population of multipotent cardiac progenitors when compared to bone marrow-derived c-kit+ populations, and that CDCs are more closely related to bone marrow stem cells in terms of their gene and protein expression profiles.10 The exact mechanistic and functional outcome implications of such differences are not yet known, but may aid ongoing clinical trials in understanding the biology of these promising cell populations.

Bone marrow-derived mononuclear cells (MNCs) have also garnered considerable interest in regenerative cell therapy as they are easily accessible and autologous, and require minimal expansion. Significantly, evidence of MNC mobilization after myocardial infarction (MI) in mice have supported that bone marrow cells play a role in myocardial healing following injury.11, 12 Randomized human clinical studies of injected MNCs demonstrated a modest increase in left ventricular ejection fraction (LVEF) and a decrease in the New York Heart Association (NYHA) functional classification system.13 Ischemic cardiomyopathy patients receiving MNCs also demonstrated a significant reduction in natriuretic peptide levels.14 Notably, infusion of MNCs with higher colony-forming capacity was associated with lower mortality, raising awareness to the notion that cell viability and quality have a significant impact on therapeutic effect. Mechanistic investigations have suggested that beneficial effects of MNC therapy were a result of neovascularization and paracrine effects rather than cardiomyocyte differentiation.15

Studies of bone marrow-derived mesenchymal stem cells (MSCs) revealed yet another adult stem cell source thought to be suitable for cardiac regeneration. MSCs were reported to readily express phenotypic characteristics of CMs and, when introduced into infarcted animal hearts by intravenous injections, to localize at sites of myocardial injury, prevent tissue remodeling, and improve cardiac recovery.16, 17 Intracoronary infusion of allogeneic mesenchymal precursors (Stro-3+ subpopulation) was also shown to decrease infarct size, improve systolic function, and increase neovascularization in animal MI models.18 These observations led to a pilot human clinical study which confirmed the safety and tolerability of MSCs in humans, and subsequently to a Phase I/II randomized trial.19, 20 More recently, additional evidence has questioned the ability of MSCs to transdifferentiate into cardiomyocytes, instead attributing the mechanism of their therapeutic properties to paracrine effects, neovascularization, and activation of endogenous CSCs.19, 21

Another class of multipotent adult stem cells of particular interest in cardiac cell therapy are CD34+ angiogenic precursors. This interest stems from the relatively impaired angiogenesis seen in ischemic heart disease patients as well as from findings that patients with coronary artery disease have reduced number and migratory activity of angiogenic precursors.22 It has also been observed that CD34+ cell injection ameliorates cardiac recovery in human MI patients by improving perfusion and/or by paracrine effects rather than cardiomyocyte differentiation.23 In one of the largest cell therapy trials to date, Losordo et al. demonstrated that patients with refractory angina who received intramyocardial injections of CD34+ cells experienced significant improvements in angina frequency and exercise tolerance.24 In a subsequent publication, the group identified that CD34+ cells secrete exosomes that might account for some of the improved phenotypes.25 The benefit of CD34+ cells was also shown for non-ischemic cardiomyopathy, when intracoronary injections resulted in a small, but significant improvement in ventricular function and survival.26 More importantly, this study demonstrated that higher intramyocardial homing was associated with better cell therapy response, providing support to prior observations with MNCs that cell delivery method and quality play a significant role in their therapeutic efficacy.

Finally, adipose-derived stem cells (ADSCs) abundantly available from liposuction surgeries have been considered as potential sources of CMs. In 2004, Planart-Blenard et al. reported potential derivation of CMs from human ADSCs by treatment with transferrin, IL-3, IL-6, and VEGF, although at very low event rate (Figure 1).27 Ongoing trials are evaluating the efficacy of this cell population in regeneration of ischemic myocardium, and although complete results have yet to be published, preliminary data are encouraging (Trial identifier: NCT00426868).

Timeline of important discoveries contributing to the field of stem cell cardiac differentiation and characterization (purple and green boxes, above timeline), including the key Top 100 Circulation Research papers discussed in this review (red boxes, below timeline). ESC, embryonic stem cell; iPSC, induced pluripotency stem cell; CMs, cardiomyocytes.

Early attempts at inducing cardiac regeneration involved transplant of skeletal myoblasts or fetal CMs to infarcted canine or rat hearts. Unfortunately, these studies ultimately disappointed the field as myoblasts remained firmly committed to form mature skeletal muscle in the heart28, while extensive cell death coupled with limited proliferation after transplant prevented fetal cardiomyocytes from repairing injury.29 Transplantation of non-contractile committed cells such as fibroblasts and smooth muscle cells into infarcted rat hearts was then briefly thought to enhance heart function, possibly due to aforementioned paracrine effects.30 More recently, several studies have demonstrated in vitro31 and in vivo32 transdifferentiation of mouse fibroblasts into seemingly functional CMs by over-expressing combinations of the cardiac transcription factors Gata4, Mef2c, Tbx5, Hand2, and Nkx2.5. Mouse CMs generated by direct transdifferentiation are positive for CM-specific sarcomeric markers, exhibit electrophysiological and gene expression profiles similar to those of fetal CMs, although this was disputed by other investigators.33In vitro transdifferentiation towards CM-like cells was also reported for human fibroblasts, albeit by more time consuming and less efficient protocols that generated mostly partially reprogrammed CMs.34 Current efforts in this research area focus on optimizing transdifferentiation efficiency and CM maturation, further characterizing derived CMs, and validating that in vitro and in vivo transdifferentiation occur in the absence of experimental artifacts, which can include incomplete silencing of transgene expression from Cre-lox systems, cell fusion events, as well as the possibility of retrovirus transfecting not only dividing fibroblasts but also non-dividing cardiomyocytes in vivo. For this technology to be fully applied in the clinic, a greater understanding of issues that have plagued the field must be reached: (1) the potential consequences of depleting endogenous cardiac fibroblasts to replenish cardiomyocytes; (2) the ability to transfect bystander cells such as smooth muscle and endothelial cells with cardiac transcription factors; and (3) the challenge of triggering immune response against the host cells transfected with viral versus non-viral vectors.

The isolation by Evans and Kaufman of mouse embryonic stem cells (mESCs) in 198135 and the generation of human embryonic stem cells (hESCs) by Thomson in 199836 opened new horizons for in vitro generation of CMs. Many protocols have been developed over the years to maximize the yield and efficiency of pluripotent ESC differentiation to CMs.37 One of the most utilized methods has been the formation of 3D aggregates named embryoid bodies within which cardiac differentiation occurs. In 2002, Xu et al. were amongst the first to optimize cardiac differentiation protocols for hESCs by using DNA demethylating agent 5-azacytidine and enrichment with Percoll separation gradients to obtain up to 70% pure cardiomyocyte populations (Figure 1).38 Later on, rigorous protocol standardization and the use of key signaling factors such as BMP4 and Activin A enabled conversion of hESCs to CMs with over 90% efficiency.39 Consequently, the formation of 3D aggregates, a labor intensive process, has now been largely replaced by differentiation in monolayer cultures, which are more amenable to scale-up and automation.40

The discovery of induced pluripotent stem cell (iPSC) technology41, based partly on principles highlighted by early somatic cell nuclear transfer experiments42, has meant that mature somatic cells such as skin fibroblasts and peripheral blood mononuclear cells (PBMCs) can be reprogrammed with relative ease to acquire an ESC-like phenotype. iPSCs retain the same capacity for high efficiency cardiac differentiation as ESCs, with the added advantages of avoiding ethical debates related to use of human embryos and enabling autologous transplantation of CMs without the need for immunosuppression. These characteristics make iPSCs ideal cellular models to provide a renewable source of CMs for basic research, pharmacological testing, and cell therapy (Figure 2).43

iPSCs are ideal cellular models to provide a renewable source of cardiomyocytes for in vitro disease modeling, pharmacological testing, and therapeutic applications in regenerative medicine.

The use of pluripotent stem cell-derived cardiomyocytes (PSC-CMs), which include both hESC-CMs and iPSC-CMs, for downstream applications requires that their properties be physiologically analogous to human cardiomyocytes in vivo. Assays for CM characterization, such as assessment for cross striations, ultrastructure, and chronotropic drug response, were established decades ago for primary rodent myocytes and published in a highly cited Circulation Research paper by Simpson and Savion in 1982.44 In 1994, Maltsev et al. were able to apply the same assays for extensive characterization of mESC-CMs.45 In addition, rigorous experimental optimization enabled them to identify internal and external solutions for patch-clamp electrophysiological analysis to confirm that CM populations comprised of ventricular, atrial, and nodal sub-types, and exhibited most basic cardiac-specific ionic currents (L-type, ICa, INa, Ito, IK, IK1, IK, ATP, IK, Ach, and If). In 2003, He et al. were among the first to perform similar characterizations of hESC-CMs.46

In vitro derived PSC-CMs have been assessed as potential screening platforms for drug discovery and toxicology studies. Despite their immature fetal phenotype, extensive pharmacological validation confirms their potential utility in drug evaluation.47 Clinically relevant drugs (e.g., adrenergic receptor agonists, anti-arrhythmic agents) have been shown to exert chronotropic and inotropic effects on PSC-CMs. In addition, experimental drugs have been used for in vitro amelioration of diseased phenotypes in human iPSC models of cardiovascular diseases48 and prediction of cytotoxic drug-induced side-effects.49, 50 Accumulated evidence suggests that PSC-CMs can offer the pharmaceutical industry a valuable physiologically relevant tool for validation of novel drug candidates and identification of potential cardiotoxic effects in early drug development stages, thereby easing the huge associated economic and patient care burdens.51, 52

The most successful and widely acknowledged use of PSCs-CMs has so far been in disease modeling. The development of disease models by genome editing of mESCs, a technology that led to award of the Nobel Prize in 2007 for Sir Martin Evans, Mario Capecchi, and Oliver Smithies (Figure 1), has offered new tools for in vivo mechanistic investigation into cardiac illnesses. The discovery of induced pluripotency technologies, which likewise led to the Nobel Prize in 2012 for Sir John Gurdon and Shinya Yamanaka, allowed the generation of patient-specific iPSC-CMs for studying human disease models of familial hypertrophic cardiomyopathy53, familial dilated cardiomyopathy54, long QT syndrome55, Timothy syndrome56, arrhythmogenic right ventricular dysplasia57, and others44 (Figure 2). Beyond the potential ability of these models to reveal insights into pathological disease mechanisms, they also offer unique opportunities to explore promising new genetic therapies58 and to identify loci or pathways related to predisposition towards cardiac disorders, thus enabling refinement of phenotype-to-genotype correlations to improve risk stratification and disease management.

The use of PSC-CMs has also expanded to in vivo applications, with transplantation shown to improve cardiac function in rat and guinea pig models of acute myocardial infarct (MI).59, 60 Effective strategies to deplete potential tumorigenic cells61, 62, induce immunotolerance63, 64, and enhance cell survival65 are being sought. Novel tissue engineering approaches to create engineered heart tissues (EHTs) for aiding cell delivery, survival, alignment and functionality of transplanted PSC-CMs are being developed in parallel.66 Notably, these technologies were pioneered by Thomas Eschenhagens group, who published one of the very first EHT papers in Circulation Research in 2002.67

See the article here:
Cardiac stem cell biology: a glimpse of the past, present, and future - PMC

Cardiac Stem Cells Comments Off on Cardiac stem cell biology: a glimpse of the past, present, and future – PMC | December 27th, 2024

Milestone demonstrates the growing customer adoption of the Company’s proprietary technology Milestone demonstrates the growing customer adoption of the Company’s proprietary technology

The rest is here:
T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally

Global News Feed Comments Off on T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally | December 18th, 2024

ROCHESTER, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, today announced that on December 16, 2024, the Company received written notice (the “Notice”) from the Office of General Counsel of The Nasdaq Stock Market (“Nasdaq”) indicating that the Nasdaq Hearings Panel has determined to delist the Company’s shares from Nasdaq due to the Company’s failure to meet Nasdaq’s continued listing standards. As previously disclosed, the Company has not been compliant with the requirements under Nasdaq Listing Rule 5550(b)(1) to maintain a minimum of $2.5 million in stockholders’ equity for continued listing on the Nasdaq Capital Market. The Notice indicated that trading in the Company’s shares of common stock (the “Common Stock”) on Nasdaq will be suspended effective at the open of trading on Wednesday, December 18, 2024.

See original here:
Vaccinex Announces Receipt of Delisting Notification from Nasdaq

Global News Feed Comments Off on Vaccinex Announces Receipt of Delisting Notification from Nasdaq | December 18th, 2024

WINTER PARK, Fla., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Adia Nutrition is excited to announce the installation of an exclusive artwork by the renowned performance artist and speed painter, Rock Demarco, at its clinic. This unique piece, which blends painting with 3D sculptural elements, now adorns the clinic's main reception area, symbolizing transformation and rebirth through the poignant imagery of butterflies and stem cells. After his initial visit to the clinic, Rock Demarco felt deeply inspired and decided to donate this custom piece to Adia Nutrition.

Visit link:
Adia Nutrition Unveils Exclusive Artwork by Renowned Performance Artist Rock Demarco at First Clinic

Global News Feed Comments Off on Adia Nutrition Unveils Exclusive Artwork by Renowned Performance Artist Rock Demarco at First Clinic | December 18th, 2024

IRVINE Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) announced today that the Company's stock has resumed trading under the symbol NYMXF on the Over the Counter QB (OTCQB®) Venture Market. This is a higher level tier from the Company's prior listing. With the new OTCQB listing, Nymox’s stock is now eligible for proprietary broker-dealer quotations.

View original post here:
NYMOX Announces Trading Resumed and New Listing on OTCQB Market

Global News Feed Comments Off on NYMOX Announces Trading Resumed and New Listing on OTCQB Market | December 18th, 2024

SAN FRANCISCO and KIGALI, Rwanda, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Bio Usawa, Inc., a leading biotechnology company committed to delivering affordable and accessible monoclonal antibody-based therapies for cancer, ophthalmic, autoimmune, and infectious diseases in Africa, has named Mr. Eric Karikari-Boateng its Head of Global Regulatory Strategy.

Follow this link:
Bio Usawa Names Former Ghana Food and Drug Authority Director Eric Karikari-Boateng as Head of Global Regulatory Strategy

Global News Feed Comments Off on Bio Usawa Names Former Ghana Food and Drug Authority Director Eric Karikari-Boateng as Head of Global Regulatory Strategy | December 18th, 2024

PRESS RELEASE

Original post:
AB Science provides a summary of the webcast held on December 16, 2024

Global News Feed Comments Off on AB Science provides a summary of the webcast held on December 16, 2024 | December 18th, 2024

Reference is made to the stock exchange announcement by Ultimovacs ASA (the "Company") on 17 December 2024 regarding the agreement to combine its business with Zelluna Immunotherapy AS (the "Business Combination") and the fully committed private placement (the "Private Placement" and together with the Business Combination, the "Transactions").

Read the original post:
Ultimovacs ASA – Mandatory notification of trade 

Global News Feed Comments Off on Ultimovacs ASA – Mandatory notification of trade  | December 18th, 2024